Key result
Serum lipids fail to independently predict NAFLD, NASH, or liver fibrosis in morbidly obese patients.
Why the study?
Dyslipidemia is frequently observed in NAFLD patients, but whether serum lipids are associated with the spectrum of NAFLD in morbidly obese individuals required evaluation.
Population
90 morbidly obese patients
Comparison
Serum lipid levels across spectrum of NAFLD, NASH, and liver fibrosis
Authors
Loading...
Caution against using lipid profiles alone for NAFLD prediction in morbid obesity; leaves open validation of reliable non-invasive markers.
Cohort (n=90)
Blinded assessors
No
Lipid profile parameters have insufficient predictive value to be used solely as non-invasive tests for predicting NASH or liver fibrosis in morbidly obese patients.
Ganjooei et al. (2021) conducted a cohort in Morbid obesity and Non-alcoholic fatty liver disease (NAFLD) (n=90). Serum lipid profile vs. Lower serum lipid levels was evaluated on Independent prediction of NAFLD, NASH, and liver fibrosis. None of the serum lipid profile parameters independently predicted NAFLD, NASH, or liver fibrosis after adjustment for potential confounders in morbidly obese patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: